Navigation Links
Hologic to Participate in Three Investor Conferences
Date:11/10/2010

BEDFORD, Mass., Nov. 10, 2010 /PRNewswire-FirstCall/ -- Hologic, Inc. (Nasdaq: HOLX) today announced that company management will participate in the following conferences:

  • Rob Cascella, President and Chief Executive Officer, will present at the J.P. Morgan SMid Conference in New York City on Thursday, December 2, 2010, at 4:30 p.m. (Eastern). Interested parties are invited to listen to the live audio webcast of Hologic's investor presentation on the investor section of the company's website at www.hologic.com/investors-overview. An archive of the presentation will be available for replay following the conference.
  • Glenn Muir, Executive Vice President and Chief Financial Officer, will host investor meetings at the Lazard Capital Markets Medical Technology Corporate Access Day in Denver on Thursday, December 2, 2010. Management will not be presenting at this conference and therefore there will be no webcast.
  • Deborah Gordon, Vice President of Investor Relations, will host investor meetings at the Nasdaq OMX 25th Investor Program in London on Tuesday, December 7, 2010. Management will not be presenting at this conference and therefore there will be no webcast.

  • About Hologic, Inc.Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic's core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, breast Magnetic Resonance Imaging, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia, permanent contraception, osteoporosis assessment, preterm birth risk assessment, mini C-arm for extremity imaging and molecular diagnostic products including HPV and reagents for a variety of DNA and RNA analysis applications. For more information, visit www.hologic.com.Contact:

    Deborah GordonVice President, Investor RelationsHologic, Inc.(781) 999-7716
    '/>"/>

    SOURCE Hologic, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Three Year Analysis of Treatment Efficacy, Cosmesis, and Toxicity Support use of the Hologic Mammosite Radiation Therapy System
    2. ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrigs Disease
    3. Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials
    4. Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer
    5. Clinical and Histopathological Results Using Pollogens TriPollar(TM) Radio Frequency Technology Published in the June Issue of the Journal of Cosmetic and Laser Therapy
    6. Hologic Receives CE Marking for the ThinPrep(R) Integrated Imager
    7. OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer; Study Paves Way for Potential Registration Trial as Radiation Sensitizer
    8. Hologic Expands Healthcare Investment in Asia
    9. Hologic to Host Investor Reception at RSNA 2009
    10. Hologic to Present at Citis 2009 Sixth Annual Small/Mid Cap Conference
    11. Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/10/2016)... Feb. 10, 2016  CVS Health (NYSE: CVS ... in Santa Clara County, CA , ... the Santa Clara University campus. CVS Pharmacy stores and ... patients against the disease. Students at Santa Clara University ... vaccinated. In addition, anyone who has had close contact ...
    (Date:2/10/2016)... Feb. 10, 2016 Immune Pharmaceuticals Inc. (NASDAQ: ... today that it has filed a patent application directed ... cancers. --> --> ... administration of Ceplene (histamine dihydrochloride) in combination with immune ... predicting the efficacy of Ceplene and IL-2 therapy in ...
    (Date:2/10/2016)... TOKYO , Feb. 10, 2016  Astellas Pharma ... , "Astellas") announced today that it has successfully completed, ... a tender offer to purchase all issued and outstanding ... OCAT, President and CEO: Paul Wotton , "Ocata") ... the stockholder in cash ("Tender Offer"). Astellas commenced the ...
    Breaking Medicine Technology:
    (Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... four time Emmy award winner and inspirational speaker Jan Fox will serve as ... by Speaking Boldly will provide participants with tools to more effectively communicate with ...
    (Date:2/10/2016)... ... 10, 2016 , ... For additional information contact Phyllis Strupp 480-488-5858 , Brain ... Age: The Ultimate Guide to Brain Training" by award-winning author Phyllis Strupp ... date is March 16, 2016. A free review copy is available to the ...
    (Date:2/10/2016)... West Palm Beach, Florida (PRWEB) , ... February ... ... Golf & Country Club) announced that it has been awarded the prestigious Distinguished ... of the World award program conducted by BoardRoom magazine, one of the most ...
    (Date:2/10/2016)... Middleboro, MA (PRWEB) , ... February 10, 2016 ... ... of their revolutionary, biocompatible columns and accessories. These PEEK-lined stainless steel (PLS) columns ... to provide a solution that ensures the integrity of biological samples while operating ...
    (Date:2/10/2016)... ... ... Workrite Ergonomics this week announced the launch of the Conform Monitor Arm Series, ... was to develop a product from the ground up that would provide the most ... Hulsey, Product Manager for Workrite Ergonomics. “The Conform series features a wide variety ...
    Breaking Medicine News(10 mins):